Hematology

ON DAY 6 of the European Hematology Association (EHA) Virtual Congress 2021, Pieter Sonneveld, Professor of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands, chaired the European Society for Medical Oncology and EHA (ESMO-EHA) joint session on clinical practice guidelines for the diagnosis, treatment, and follow-up of multiple myeloma.

AT THE EUROPEAN Hematology Association (EHA) 2021 Virtual Congress, Evangelos Terpos, University of Athens School of Medicine, Greece, discussed COVID-19 and how neutralising antibody levels are affected by various factors such as age, gender, and disease.

Myelodysplastic syndromes (MDS) are clonal haematopoietic disorders of pluripotent stem cells, characterised by ineffective haematopoiesis…

Multiple myeloma is a haematological malignancy predominantly affecting older people and has a median age of onset of 70 years.

β-thalassaemias are a clinically heterogenous group of inherited disorders caused by >200 described mutations in the β-globin gene, leading to a decreased or absent production of the β-globin chain.

Polycythaemia vera (PV) is a condition characterised by an increasing number of the red blood cells in the blood.

Eduard Glanzmann first reported Glanzmann thrombasthenia (GT) in 1918 after he identified a functional abnormality of platelets with defective clot retraction.

Mutations in FLT3 are the most common genetic alteration in AML. Patients with a FLT3 internal tandem duplication (ITD) mutation subtype have poor prognosis, especially when there is a high allelic burden.